Simple Summary The drug BromAc® has been used in the treatment of pseudomyxoma
peritonei, a rare peritoneal cancer. Often, patients with pseudomyxoma peritonei require …

Although numerous clinical attempts have been made to disintegrate mucin secreted by
pseudomyxoma peritonei (PMP), none are clinically recommended. Through examination of …

BACKGROUND: This study examines the potential efficacy of hydrogen peroxide and
ascorbic acid in the dissolution of mucinous ascites from pseudomyxoma peritonei …

Background: Mucinous neoplasms with peritoneal spread constitute an infrequent entity
known as Pseudomyxoma Peritonei. The massive intraabdominal affectation contrast with …

Intraperitoneal administration of BromAc (bromelain+ acetylcysteine) is currently undergoing
a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on …

Pseudomyxoma peritonei (PMP) is considered a rare disease caused by mucin-secreting
tumour cells commonly arising from the appendix 1. Cytoreductive surgery plus …

Background Intraperitoneal accumulation of mucinous ascites in pseudomyxoma peritonei
(PMP) promotes an inflammatory/fibrotic reaction that progresses to bowel obstruction and …

Purpose: The modern treatment of pseudomyxoma peritonei is cytoreductive surgery plus
intraperitoneal chemotherapy resulting in a survival of up to 70 percent after 20 years. The …

Background/Aim: Pseudomyxoma peritonei (PMP) is a rare clinical condition of progressive
peritoneal mucin accumulation. PMP has a reasonable survivability but with a notable risk of …

Aim: The aim of this experimental study was to investigate the effects of intraperitoneally
injected irinotecan on the healing of colonic anastomoses after colon resection. Methods …